Follow on Google News News By Tag * Dvax * Gtcb * Idev * Penny Stocks * Investor Relations * Hot Stocks * Financial Communications * Small-cap * Micro-cap * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News |  Penny Stocks Alert – Hot Stocks Alert for DVAX, GTCB, IDEVMobile Press Wire issues Hot Stocks and Penny Stocks alerts for emerging public companies on the move
By: MobilePressWire.com To Receive FREE Stock Alerts specially formatted for you mobile phone no matter where you are, please see below or go to http://www.mobilepresswire.com for more details. Dynavax Technologies NEWS – February 9th, 2009 Hot Stock Alert: Small Cap News: Dynavax Receives Updated Communications from the FDA on HEPLISAV(TM) BERKELEY, Calif., -- Dynavax Technologies Corporation released breaking news this morning it has received communication from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on the two HEPLISAV(TM) Investors are urged to look for early trading activity today as the stock closed Friday, February 6, 2009 at $0.6201 a share. Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops a diversified, well-funded pipeline of novel Toll-like Receptor (TLR) product candidates. Based on Dynavax's proprietary technology platforms, these products specifically modify the innate immune response to infectious, respiratory, autoimmune, and inflammatory diseases. Dynavax's product programs are supported by global partnerships with leading pharmaceutical companies such as GlaxoSmithKline, AstraZeneca AB, and Novartis as well as funding from Symphony Dynamo, Inc. and the National Institutes of Health. To Read View a Corporate Profile and Full Disclosure, Please Visit: http://mobilepresswire.com/ GTC Biotherapeutics NEWS – February 9th, 2009 Hot Stock News: GTC Biotherapeutics Receives FDA approved ATryn(R) (Antithrombin FRAMINGHAM, Mass. & DEERFIELD, Ill., -- GTC Biotherapeutics and OVATION Pharmaceuticals, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ATryn(R) (Antithrombin [Recombinant]) Investors are urged to look for early trading activity today as the stock closed Friday, February 6, 2009 at $0.70 a share. GTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. In addition to ATryn, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa, VIII, and IX, which are being developed for the treatment of hemophilia, and alpha-1 antitrypsin. GTC also has a monoclonal antibody portfolio that includes a monoclonal antibody to CD20 and a monoclonal antibody to CD137. GTC's intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Trudy Corporation engages in publishing children's books and audiobooks, as well as in designing, manufacturing, and marketing children's musical instruments, electronics, and plush stuffed animals. To read the entire release regarding the company's recent announcement and to sign up to get FREE alerts like this sent to your cellular device before others are able to view it, visit: http://mobilepresswire.com/ Indevus Pharmaceuticals NEWS - February 9th, 2009 Investor News: Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study LEXINGTON, Mass., -- Indevus Pharmaceuticals, Inc. announced today that a National Institutes of Health (NIH)-sponsored clinical study found that participating women who received PRO 2000, the Company's candidate vaginal microbicide for HIV prevention, had an approximately 30% lower risk of acquiring HIV infection than women who received a placebo or no vaginal product. Investors are urged to look for early trading activity today as the stock closed Friday, February 6th, 2009 at $5.33 a share. To read the entire release regarding the company's recent announcement and to sign up to get FREE alerts like this sent to your cellular device before others are able to view it, visit: http://mobilepresswire.com/ ABOUT MOBIWIRE MobiWire is solely owned and operated by Mobile Press Wire a leading news alert wire service for mobile phones subscribers. Mobile Press Wire offers FREE news alerts for its subscribers of publicly traded companies that wish to instantly announce special news to the investment community. Visit http://www.mobilepresswire.com for more details. GET NEWS NOW, GET NEWS FAST, GET NEWS BEFORE OTHERS... To get FREE Mobile Stock Alerts formatted especially for your cell phone; text the word "STOCKS" in the subject line to 68494. Please note subscribers are never charged any fees from Mobile Press Wire for signing up to receive public company alerts or canceling any of our services. Standard carrier SMS text messaging rates may apply. Please check with your wireless plan for further details. Subscribers are able to fully control the number of alerts they want to receive. Choose to get 1 a week, 2 a week, 5 a week and so on. Subscribers are also able to stop receiving alerts at anytime with no questions asked by texting the word STOP to 68494. Contact email: info@mobilepresswire.com URL: http://www.mobilepresswire.com Company: MobiWire # # # Mobile Media Technology Solutions. Utilizing proprietary SMS Text Message Services, we deliver breaking news alerts for Public Companies and Investor Relations Professionals via specially formatted text messages. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
